Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

In vivo validation of a novel, high precision Positive Allosteric Modulation-based therapy for immune-inflammatory diseases

Cel

Immune-inflammatory diseases arise when the balance between stimulatory and inhibitory checkpoint signals is disrupted, causing excessive immune responses and ultimately breaking immune tolerance and tissue homeostasis. Current therapies either broadly suppress the immune system or block stimulatory checkpoints, but none exploit the activity of inhibitory checkpoints as a mechanism built by nature to restore immune homeostasis. This leaves a clear therapeutic gap, and an opportunity to locally control immune responses while avoiding systemic immunosuppression.

Within my ERC-2023-ADG, we discovered VHH-based positive allosteric modulators (PAMs) that activate different inhibitory checkpoints rather than blocking them. These PAMs stabilize the native receptor–ligand interaction in vitro and stimulate intracellular signalling with, as a unique feature, ligand dependent and spatio temporal precision. An in vivo proof-of-concept is essential to bridge the translational gap towards their therapeutic application.

To consolidate our PAMs as a new modality for restoring immune checkpoint signalling in immune inflammatory diseases, we will (i) confirm target engagement by PAMs ex vivo using human samples; (ii) deliver in vivo proof of mechanism for inhibitory immune checkpoint PAMs in a Graft-versus-Host-Disease mouse model and (iii) evaluate further developed PAM formats to enhance the impact of the therapeutic effects.

These PoC data will provide the momentum needed to launch Allosteris -our next spin-off in the field of allosteric immunotherapies- by strengthening our IP, derisking the technology, and expanding partnering opportunities. In essence, this ERC PoC grant will sharpen Allosteris’ unique value proposition by advancing a therapeutic strategy that restores inhibitory immune signalling rather than applying blanket immunosuppression, paving the way for safer, precision treatments for immune-inflammatory diseases.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2026-POC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

VIB VZW
Wkład UE netto
€ 150 000,00
Koszt całkowity
Brak danych

Beneficjenci (1)